Immune Reconstitution Inflammatory Syndrome (IRIS) Guidelines

Definition and Pathophysiology

• Immune Reconstitution Inflammatory Syndrome (IRIS) is a paradoxical worsening of clinical symptoms, signs, or radiologic manifestations that occurs when antiretroviral therapy (ART) restores immune function in HIV-infected patients, resulting in an exaggerated inflammatory response to previously present infectious or non-infectious antigens, as described by the Infectious Diseases Society of America 1, 2
• IRIS represents a dysregulated host inflammatory response that develops as the immune system reconstitutes following initiation of ART, according to the Clinical Infectious Diseases guidelines 1, 2

Timing and Incidence

• IRIS typically occurs within 3 to 6 months after initiating ART, though timing varies by the underlying pathogen, as reported by the National Comprehensive Cancer Network 3, 4
• The overall incidence ranges from 6% to 39% depending on the population studied and the burden of opportunistic infections, as stated by the National Comprehensive Cancer Network 3

Major Risk Factors

• A CD4+ count <50 cells/μL at ART initiation significantly increases IRIS risk, as indicated by the Clinical Infectious Diseases guidelines 2, 5
• Early ART initiation (within 2 weeks) after starting treatment for opportunistic infections is a major risk factor for IRIS, according to the Clinical Infectious Diseases guidelines 2, 5
• Advanced immunosuppression with disseminated disease increases the risk of IRIS, as reported by the Clinical Infectious Diseases guidelines 1, 6

Common Infectious Manifestations

• Mycobacterium tuberculosis is a common cause of IRIS, presenting with high fevers, worsening respiratory symptoms, and other complications, as described by the Clinical Infectious Diseases guidelines 2, 5
• Cryptococcus neoformans can cause IRIS, manifesting with increased intracranial pressure and worsening meningeal inflammation, as reported by the Praxis Medical Insights guidelines 6
• Mycobacterium avium complex (MAC) can cause paradoxical worsening despite appropriate antimycobacterial therapy, as stated by the Clinical Infectious Diseases guidelines 1, 7

Management Principles

• For most patients with mild to moderate IRIS, continue both ART and antimicrobial therapy unless life-threatening complications develop, as recommended by the Clinical Infectious Diseases guidelines 5, 3
• Initiate nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen for symptomatic relief, as suggested by the Clinical Infectious Diseases guidelines 5, 7
• For severe IRIS manifestations, administer prednisone 0.5-1.0 mg/kg/day (or equivalent) for 2-6 weeks with gradual taper, as recommended by the Praxis Medical Insights guidelines 6

Prevention Strategies

• Screen and treat opportunistic infections before initiating ART when feasible, as recommended by the Clinical Infectious Diseases guidelines 1
• For patients with CD4 <50 cells/μL without CNS tuberculosis, start ART within 2 weeks of tuberculosis treatment to balance mortality reduction against IRIS risk, as suggested by the Clinical Infectious Diseases guidelines 2, 5
• For patients with CD4 ≥50 cells/μL, initiate ART at 8-12 weeks after starting tuberculosis treatment, as recommended by the Clinical Infectious Diseases guidelines 2, 5

Management of Immune Reconstitution Inflammatory Syndrome (IRIS)

Risk Stratification and Prevention

• Disseminated disease with high pathogen burden (e.g., >2 log10 CFU/mL mycobacteremia) elevates IRIS risk, according to the Centers for Disease Control and Prevention (CDC) 8
• The CDC recommends optimizing timing of ART initiation based on CD4 count and type of infection to minimize IRIS risk 9
• Ensuring adequate antimicrobial therapy is established before introducing ART, particularly for MAC disease, is crucial, as per the CDC guidelines 10, 8

Timing of ART Initiation

• For patients with tuberculosis coinfection and CD4 <50 cells/μL, the Infectious Diseases Society of America (IDSA) recommends starting ART within 2 weeks of tuberculosis treatment initiation to reduce mortality, accepting increased IRIS risk 9
• For patients with disseminated MAC disease, the CDC suggests withholding ART until after the first 2 weeks of antimycobacterial therapy to reduce drug interactions, pill burden, and IRIS complications 10, 8

Clinical Recognition and Treatment

• The IDSA describes tuberculosis IRIS as high fevers, worsening respiratory symptoms, enlarging or new lymphadenopathy, expanding CNS lesions, worsening pulmonary infiltrates, new or increasing pleural effusions, intra-abdominal or retroperitoneal abscesses 9
• The CDC characterizes MAC IRIS as paradoxical worsening despite appropriate antimycobacterial therapy with fever, lymphadenitis, or other inflammatory manifestations 8
• For severe IRIS, the IDSA recommends administering prednisone 1.25 mg/kg/day, which significantly reduced hospitalization and surgical intervention needs 9

Monitoring and Prevention Strategies

• The CDC advises monitoring for new or worsening symptoms within the first 3-6 months after ART initiation, and tracking CD4 count recovery and viral load suppression 8, 10
• For MAC, the CDC recommends repeat blood cultures at 4-8 weeks only if clinical response is inadequate 10, 8
• For CMV retinitis, the CDC suggests ophthalmologic examination after induction therapy completion, at 1 month, then monthly while on treatment 11

Management of Immune Reconstitution Inflammatory Syndrome (IRIS) in HIV Patients on ART

Optimizing ART Timing by Infection Type

• For patients with tuberculosis without CNS involvement and CD4 <50 cells/μL, the American Medical Association recommends starting ART within 2 weeks of tuberculosis treatment to reduce mortality, accepting increased IRIS risk 12
• For patients with tuberculous meningitis, the American Medical Association suggests initiating high-dose corticosteroids and tuberculosis treatment immediately at diagnosis, and starting ART when tuberculous meningitis is under control based on clinical improvement and CSF parameter normalization, within 2-4 weeks 12
• For patients with cryptococcal meningitis, the American Medical Association recommends initiating ART 2-4 weeks after starting antifungal therapy, with earlier initiation at 2 weeks for those clinically improved with controlled intracranial pressure and negative CSF cultures 12
• For patients with most other opportunistic infections, the American Medical Association suggests starting ART within 2 weeks of initiating treatment 12, 13

Critical Pitfalls to Avoid

• The American Medical Association advises against delaying ART indefinitely to avoid IRIS, as mortality reduction from early ART outweighs IRIS risk 12

Immune Reconstitution Inflammatory Syndrome (IRIS) – Evidence‑Based Guidance

Definition & Pathophysiology

• IRIS is a paradoxical worsening of clinical symptoms that occurs when antiretroviral therapy (ART) restores immune function in HIV‑infected patients, leading to an exaggerated inflammatory response to previously present infectious antigens; most episodes are mild‑to‑moderate and can be managed symptomatically while continuing both ART and antimicrobial therapy, whereas severe cases require corticosteroids (prednisone 1.25 mg/kg/day)【14】.

• Two clinical patterns are recognized:

  • Paradoxical IRIS – deterioration of a known opportunistic infection after ART initiation.
  • Unmasking IRIS – emergence of clinical disease from a previously subclinical infection after immune restoration【14】.

Epidemiology & Risk Factors

• IRIS most commonly manifests within 3–6 months after starting ART【14】.
• Reported overall incidence varies from 6 % to 39 % depending on study population and burden of opportunistic infections【14】.
• In the STRIDE cohort of tuberculosis–HIV coinfection, IRIS occurred in 7.6 % of patients【14】.
• Major predictors of IRIS:
  
  • Baseline CD4⁺ count < 50 cells/µL at ART initiation (strongest predictor)【14】.
  • Early ART (≤ 2 weeks) after beginning treatment for an opportunistic infection, associated with a relative risk of 1.88 (95 % CI 1.31–2.69)【14】.
  • Advanced immunosuppression with disseminated disease and high pathogen burden【14】.
  • Rapid virological suppression (excellent ART response)【14】.

Clinical Presentation (Tuberculosis‑Associated IRIS)

• Typical manifestations include:
  
  • High‑grade fevers and worsening respiratory symptoms.
  • New or enlarging lymphadenopathy with marked inflammation.
  • Expansion of central nervous system lesions.
  • Progression of pulmonary infiltrates.
  • Development or increase of pleural effusions.
  • Formation of intra‑abdominal or retroperitoneal abscesses【14】.

Diagnostic Approach

• IRIS is a diagnosis of exclusion; alternative causes must be ruled out before attribution【14】.
• Essential exclusions:
  
  • Drug‑resistant tuberculosis or failure of anti‑TB therapy.
  • New opportunistic infections (e.g., lymphoma, other infections).【14】
• Diagnostic criteria (all must be satisfied):

Management

Mild‑to‑Moderate IRIS (≈ 69 % of episodes)

• Continue ART and antimicrobial therapy unless life‑threatening complications arise【14】.
• Symptomatic relief with NSAIDs (e.g., ibuprofen)【14】.
• Provide supportive care and close monitoring【14】.
• Consider procedural drainage for worsening pleural effusions or abscesses【14】.

Severe IRIS (≈ 31 % of episodes, often requiring hospitalization)

• Prednisone 1.25 mg/kg/day (≈ 50–80 mg) for 2–4 weeks, followed by a taper over 6–12 weeks (or longer if needed)【14】.
• This regimen significantly reduces hospitalization and need for surgical intervention in placebo‑controlled trials (high‑quality evidence)【14】.
• Maintain ART and antimicrobial therapy throughout corticosteroid treatment【14】.
• Monitor for steroid‑related adverse effects and extend taper if symptoms recur【14】.

Critical Exception – Central Nervous System (CNS) Tuberculosis

• Do NOT initiate ART within the first 8 weeks of antituberculosis therapy for patients with tuberculous meningitis or other CNS TB, even if CD4⁺ < 50 cells/µL【14】.
• Early ART (≤ 2 weeks) in CNS TB is linked to higher adverse‑event rates and increased mortality due to severe or fatal neurological IRIS【14】.

Prevention – Timing of ART Initiation for Tuberculosis

Critical Pitfalls to Avoid

• Do not discontinue ART for mild‑moderate IRIS; most episodes resolve with symptomatic management while therapy continues【14】.
• Avoid early ART in CNS TB; delayed initiation (≥ 8 weeks) is mandatory to reduce mortality【14】.
• Systematically exclude treatment failure, drug resistance, and new infections before labeling a deterioration as IRIS【14】.
• Reserve corticosteroids for severe IRIS; they should not be used empirically in mild cases【14】.